

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **LifeTech Scientific Corporation**

**先健科技公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1302)**

### **VOLUNTARY ANNOUNCEMENT**

#### **Lifeflow™ obtained official registration approval by the China NMPA**

This announcement is made by LifeTech Scientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders and potential investors with updated information in relation to the latest business and new product development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 13 January 2021, the Group’s self-developed Lifeflow™ iliac artery bifurcation stent graft system (“**Lifeflow™**” or the “**Device**”) obtained official registration approval from the China National Medical Products Administration (“**NMPA**”). Lifeflow™ is used for the treatment of abdominal iliac aneurysms or common iliac aneurysms and is the first internal iliac artery reconstruction device independently developed in China to obtain registration approval.

The Device was approved to be entered into the China National Innovative Medical Device Special Review Procedure in August 2017 and is unique in that it can directly connect to the branch of the abdominal aorta bifurcation stent. As a result, there are fewer connection points, making it relatively stable and avoids complications such as leakage at connection joints. At the same time, the number of stents used can be reduced, thereby reducing treatment costs. The ease of operation of the delivery system of the Device will also effectively reduce risks during operations.

The group will continue with independent innovation, and work with industry experts to advance the development and marketing of innovative medical device products to benefit patients.

By order of the Board  
**LifeTech Scientific Corporation**  
**XIE Yuehui**  
*Executive Director, Chairman  
and Chief Executive Officer*

Hong Kong, 13 January 2021

*As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive Directors; Mr. JIANG Feng and Mr. FU Feng being non-executive Directors; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.*